www.fdanews.com/articles/149973-ventirx-celgene-to-develop-cancer-drug

VentiRx, Celgene to Develop Cancer Drug

October 4, 2012

VentiRx Pharmaceuticals has formed a world-wide collaboration with Celgene Corporation to develop VTX-2337, a highly potent and selective TLR8 agonist for cancer treatment.
Pharmaceutical Business Review